| Assay ID | Title | Year | Journal | Article |
|---|
| AID1253010 | Protective activity against isoniazid and rifampicin-induced hepatotoxicity in Wistar rat assessed as reduction of MDA level at 2.5 mg/kg, po (Rvb = 30.5 +/- 7.8 nM/mg) | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Protective effects of the bioactive natural product N-trans-Caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. |
| AID1253013 | Protective activity against isoniazid and rifampicin-induced hepatotoxicity in Wistar rat assessed as decrease of CYP2E1 mRNA expression in liver | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Protective effects of the bioactive natural product N-trans-Caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. |
| AID263691 | DPPH radical scavenging activity at 100 uM | 2006 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
| Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase. |
| AID1253011 | Protective activity against isoniazid and rifampicin-induced hepatotoxicity in Wistar rat assessed as increase of GSH activity at 2.5 mg/kg, po (Rvb = 29.4 +/- 11.4 uM/gram) | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Protective effects of the bioactive natural product N-trans-Caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. |
| AID1500522 | Inhibition of butter milk XOD (unknown origin) at 100 uM using xanthine as substrate after 8 mins relative to control | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties. |
| AID306326 | Antimicrobial activity against fluoroquinolone-resistant Staphylococcus aureus SA1199B | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
| N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. |
| AID306328 | Inhibition of NorA pump in fluoroquinolone-resistant Staphylococcus aureus SA1199B assessed as drug level causing 4-fold reduction of Norfloxacin MIC | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
| N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. |
| AID1500523 | Antioxidant activity assessed as inhibition of DPPH radical at 100 uM incubated for 20 mins measured for 60 mins relative to control | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties. |
| AID125798 | Evaluated for the antioxidant property by measuring the inhibition of microsomal lipid peroxidation | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
| Synthesis and evaluation of caffeic acid amides as antioxidants. |
| AID1253012 | Protective activity against isoniazid and rifampicin-induced hepatotoxicity in Wistar rat by haematoxylin and eosin staining | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Protective effects of the bioactive natural product N-trans-Caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. |
| AID263688 | Inhibitory activity against tyrosinase at 100uM | 2006 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
| Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase. |
| AID1500513 | Inhibition of QD-labeled amyloid beta (1 to 42) (unknown origin) aggregation after 24 hrs by inverted fluorescence microscopic method | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties. |
| AID1500524 | Antioxidant activity assessed as inhibition of DPPH radical at 500 uM incubated for 20 mins measured for 60 mins relative to control | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties. |
| AID1500521 | Inhibition of butter milk XOD (unknown origin) at 10 uM using xanthine as substrate after 8 mins relative to control | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties. |
| AID1253007 | Protective activity against isoniazid and rifampicin-induced hepatotoxicity in Wistar rat assessed as reduction of serum ALT level at 2.5 mg/kg, po (Rvb = 143.7 +/- 12.5 U) | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Protective effects of the bioactive natural product N-trans-Caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. |
| AID1253008 | Protective activity against isoniazid and rifampicin-induced hepatotoxicity in Wistar rat assessed as reduction of serum AST level at 2.5 mg/kg, po (Rvb = 168.5 +/- 14.7 U) | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Protective effects of the bioactive natural product N-trans-Caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. |
| AID1253009 | Protective activity against isoniazid and rifampicin-induced hepatotoxicity in Wistar rat assessed as increase of SOD activity at 2.5 mg/kg, po (Rvb = 31.4 +/- 8.3 U/mg) | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Protective effects of the bioactive natural product N-trans-Caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. |
| AID306327 | Inhibition of NorA pump in fluoroquinolone-resistant Staphylococcus aureus SA1199B assessed as drug level causing 8-fold reduction of Norfloxacin MIC | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
| N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |